BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 5:33:00 PM | Browse: 1098 | Download: 1060
 |
Received |
|
2013-06-06 08:57 |
 |
Peer-Review Started |
|
2013-06-07 18:55 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-07-17 16:46 |
 |
Revised |
|
2013-08-09 22:36 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-10-21 17:24 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-10-22 06:35 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-11-27 19:53 |
 |
Typeset the Manuscript |
|
2013-12-28 17:52 |
 |
Publish the Manuscript Online |
|
2014-01-20 17:10 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Autobiography |
| Article Title |
Time of infliximab therapy initiation and dose escalation in Crohn’s disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mindy CW Lam, Terry Lee, Kenneth Atkinson and Brian Bressler |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Brian Bressler, MD, Division of Gastroenterology, Department of Medicine, University of British Columbia,770-1190 Hornby Street, Vancouver, BC V6Z 2K5, Canada. brian_bressler@hotmail.com |
| Key Words |
Crohn’s disease; Infliximab; Dose escalation |
| Core Tip |
Crohn’s disease patients who required infliximab therapy earlier (< 2 years) probably have a higher inflammatory burden of disease than those who require infliximab therapy later. Our results show that those who receive infliximab within 2 years of diagnosis require more intense immunosuppressant therapy to avoid dose escalation. This finding supports the importance of concurrent immunosuppressant therapy while on infliximab, as previously described by the SONIC trial. |
| Publish Date |
2014-01-20 17:10 |
| Citation |
Lam MCW, Lee T, Atkinson K, Bressler B. Time of infliximab therapy initiation and dose escalation in Crohn’s disease. World J Gastroenterol 2014; 20(1): 214-218 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i1/214.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i1.214 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345